Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-18
2007-09-18
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S188000, C514S217120, C514S315000, C514S492000, C540S541000, C540S609000, C546S011000, C546S246000
Reexamination Certificate
active
10655657
ABSTRACT:
The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.
REFERENCES:
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4902797 (1990-02-01), Totani et al.
Anderson and Meister, “Transport and direct utilization of γ-glutamylcyst(e)ine for glutathione synthesis,”Proc. Natl. Acad. Sci., USA, 80:707-711, 1983.
Anderson, “Glutathione and glutathione delivery compounds,”Adv. Pharmacol., 38:65-78, 1997.
Baranczyk-Kuzma et al., “Tricyclic antidepressants as inhibitors of brain glutathione-S-transferase,” Pol Merkuriusz Lek., 11(66):472-475, 2001.
Burg et al., “Peptidomimetic glutathione analogues as novel γGT stable GST inhibitors,”Bioog. Med. Chem., 10(1):195-205, 2002.
Campbell et al., “Analytical and preparative separation of the diastereomers of L-buthionine (SR)-sulfoximine, a potent inhibitor of glutathione biosynthesis,”Anal. Biochem., 194:268-277, 1991.
Comess et al., “Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum (II) DNA adducts,”Biochemistry, 31:3975-3990, 1992.
Eastman, “The mechanism of action of cisplatin: from adducts to apoptosis,” In: Cisplatin.Chemistry and Biochemistry of a Leading Anticancer Drug, Lippert (ed.), Wiley-VCH, Zürich, Switzerland, 111-134, 1999.
Griffith and Meister, “Potent and specific inhibition of glutathione synthesis by buthionine sufoximine (S-n-Butyl homocysteine sulfoximine,”J. Biol. Chem., 254(16):7558-7560, 1979.
Griffith, “Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its high homologs, potent inhibitors of glutathione synthesis,”J. Biol. Chem., 257(22):13704-13712, 1982.
Jamieson and Lippard, “Structure, recognition, and processing of cisplatin-DNA adducts,”Chem. Rev., 99:2467-2498, 1999.
Johnson et al., “Metal antitumor compounds: the mechanism of action of platinum complexes,”Prog. Clin. Biochem. Med., 10:1-24, 1989.
Kunze, “Phosphono analogues of glutathione as new inhibitors of glutathione S-transferases,”Arch. Pharm., 329(11):503-509, 1996.
Lepre and Lippard, “Interaction of platinum antitumor compounds with DNA,”Nucleic Acids Mol. Biol., 4:9-38, 1990.
Meister and Anderson, “Glutathione,”Annl. Rev. Biochem., 52:711-760, 1983.
O'Dwyer et al., In:Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Lipert (ed.), Wiley-VCH, Zürich, Switzerland, 31-72, 1999.
Reedijk, “Improved understanding in platinum antitumor chemistry,”Chem. Commun., 801-806, 1996.
Richman and Meister, “Regulation of γ-glutamyl-cystiene synthetase by nonallosteric feedback inhibition by glutathione,”J. Biol. Chem., 250(4):1422-1426, 1973.
Rosenberg, “Platinum complexes for the treatment of cancer: why the search goes on,” In:Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Lipert (ed.), Wiley-VCH, Zürich, Switzerland, 3-30, 1999.
Schultz et al., “Inhibitors of glutathione S-transferases as therapeutic agents,”Adv. Drug Deliv. Rev., 26(2-3):91-104, 1997.
Tew, “Glutathione-associated enzymes in anticancer drug resistance,”Cancer Res., 54(16):4313-4320, 1994.
Zamble and Lippard, “The response of cellular proteins to cisplatin-damaged DNA,” In:Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Lipert (ed.), Wiley-VCH, Zürich, Switzerland, 73-110, 1999.
Siddik et al., “Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin,”J Cancer Res Clin Oncol, 120:571-577, 1994.
Khokhar Abdul R.
Siddik Zahid H.
Board of Regents the University of Texas System
Coleman Brenda
Fulbright & Jaworski L.L.P.
LandOfFree
Platinum complexes as antitumor agents in combination with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platinum complexes as antitumor agents in combination with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum complexes as antitumor agents in combination with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792346